Deadline: 31-Mar-25
Pfizer is seeking applications to identify investigators with innovative research proposals who are interested in partnering with Pfizer and potentially other likeminded investigators on co-developing research studies focused on the respiratory syncytial virus (RSV) vaccine (Pfizer – Abrysvo) in adults (RSV).
Area of Interest
- Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease (LRTD) among adults and can lead to serious morbidity and mortality, especially among older adults and adults with underlying comorbidities, such as immunocomprising conditions. The intent of this CFC is to identify investigators with research ideas who want to partner and co-develop research studies with Pfizer. Projects may also potentially involve other investigators if multiple proposals share similar objectives and methodological approaches. In these instances, Pfizer, along with the investigators, may pursue a single research study with multiple sites if all parties agree.
Funding Information
- The intent is to support 1 to 3 studies. Study design for a single site, up to $500,000 USD, for a length of 12 months.
Eligibility Criteria
- The institution and Principal Investigator (PI) must be based in one of the eligible countries.
- Only organizations are eligible to receive funds and in-kind support, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- If selected, the PI and their organization are willing and able to engage in a Research Collaboration with Pfizer.
- For all Research Collaborations (RCs), the selected principle investigator is responsible for the design, implementation, sponsorship, and conduct of the initiative supported by the RC, including compliance with any regulatory requirements.
- Pfizer may be involved in the design of the study protocol and project development, as well as the conduct or monitoring of the research program. Preference will be given to PIs that are open to collaborative agreements with other institutions with similar research interests.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
For more information, visit Pfizer.
